Cascara Ventures is the new investment fund of Adriaan Hart de Ruijter, experienced entrepreneur and investor in life sciences. Founded in 2016, Cascara invests in the seed stage of companies that apply technology to prevention, therapy and research. Examples are vaccines, medical devices, pharmaceuticals, imaging, software, medical data, robotics, healthcare services, diagnostics and cell therapy.
We emphasize early-stage investing and active management of portfolio companies that meet our investment criteria. Our regulatory and clinical development expertise, based on experience with hundreds of clinical trials and approvals, is of great benefit to our portfolio companies. We collaborate in a network of investors and funds, each with their individual specialty.
Cascara Ventures is an accredited investor with the European Investment Fund, meaning that all investments are matched on a pari passu basis by EIF, allowing for a larger commitment to a larger number of startups.
In a consortium we have the ability to follow through to the mature stages of a company, creating global leaders in their respective markets.
Together, we can accelerate clinical development and regulatory approval, achieving value milestones faster than with conventional venture capital.